Innate Pharma highlights abstracts selected for ASCO 2025 annual meeting

• Long term follow-up results of TELLOMAK Phase 2 trial in Sézary syndrome and mycosis fungoides

• Trial in Progress poster on IPH4502, Innate’s differentiated ADC in development in advanced solid tumors expressing Nectin-4

• AstraZeneca to present a poster on updated results from the Phase 2 trial NeoCOAST-2 in resectable NSCLC

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that four abstracts with Innate’s drugs in clinical development have been accepted for the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, taking place May 30-June 3, 2025 in Chicago, Illinois.

“We are looking forward to participating in the ASCO Annual Meeting 2025, where four abstracts with Innate’s drugs in clinical development have been selected. In particular, we are pleased to share the long-term follow-up data from the TELLOMAK Phase 2 study, which underscores our continued commitment to advancing innovative therapies for patients," commented Dr Sonia Quaratino, Chief Medical Officer of Innate Pharma.

ASCO abstract details:

Lacutamab

• Abstract: 2522
  Abstract Title: Lacutamab in patients with relapsed and refractory Sézary syndrome: Long term follow-up from the TELLOMAK phase 2 trial
  Session Type: Poster Session
  Session Title: Developmental Therapeutics—Immunotherapy
  Session Date and Time: Monday June 2, 2025 – 1:30 – 4:30 PM CDT

• Abstract: 2523
  Abstract Title: Lacutamab in patients with relapsed and/or refractory mycosis fungoides: Long-term follow-up and translational data from the TELLOMAK phase 2 trial
  Session Type: Poster Session
  Session Title: Developmental Therapeutics—Immunotherapy
  Session Date and Time: Monday June 2, 2025 – 1:30 – 4:30 PM CDT

IPH4502

• Abstract: TPS3159
  Abstract Title: A phase 1, open-label, multi-center study of the safety, tolerability, and efficacy of IPH4502 as a single agent in advanced solid tumors
  Session Type: Poster Session
  Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
  Session Date and Time: Monday June 2, 2025 – 1:30 – 4:30 PM CDT

   

Monalizumab (partnered with AstraZeneca)

• Abstract: 8046
  Abstract Title: Neoadjuvant durvalumab (D) + chemotherapy (CT) + novel anticancer agents and adjuvant D ± novel agents in resectable non-small-cell lung cancer (NSCLC): Updated outcomes from NeoCOAST-2.
  Session Type: Poster Session
  Session Title: Lung Cancer—Non–Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
  Session Date and Time: Saturday May 31, 2025 – 1:30 – 4:30 PM CDT